Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630117 · ClinicalTrials.gov registry record · Phase 1
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
NCT06630117 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 245 participants.
The verdict
NCT06630117, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL V330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06630117
The ClinicalTrials.gov registry entry for NCT06630117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06630117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06630117 about?
NCT06630117 is a clinical study titled "A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)". The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
What is the current status of trial NCT06630117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2024-03-01. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT06630117?
The interventions under investigation include: Placebo (BIOLOGICAL), V330 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06630117?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.